Clinical trials: Liver Fibrosis, open to volunteers
Sarcopenia, Cirrhosis of the Liver
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
The goal of this clinical trial is to compare the nutritional parameters after 24-week supplementation of branched-chain amino acids in cirrhotic patients with low muscle mass.
- Trial name
- BCAASarcopenia (NCT06121492)
- Testing
- Branched-chain amino acid
- Where
- Thailand
- Volunteers
- 86 people
- Sponsor
- Mahidol University
Liver Cirrhosis, Gastroesophageal Varices
Feasibility and Safety Evaluation of Endoscopic Treatment of Esophagogastric Varices in Cirrhosis on the Day-care Unit
The goal of this observational study is to learn about the feasibility and safety evaluation of endoscopic treatment of esophagogastric varices in cirrhosis on the day-care ward.
- Trial name
- NCT07129447
- Volunteers
- 330 people
- Sponsor
- Qilu Hospital of Shandong University
Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy.
- Trial name
- NCT07412236
- Testing
- Hydronidone (270mg)
- Where
- China
- Volunteers
- 1,208 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Decompensated Cirrhosis, Cirrhotic Cardiomyopathy
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections.
- Conditions
- Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Left Ventricular Diastolic Dysfunction
- Trial name
- CIRROSTAT (NCT06431919)
- Testing
- Simvastatin 20mg, Carvedilol 3.125 mg
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Liver Cirrhosis
Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE).
- Trial name
- PYROCALM (NCT07201649)
- Testing
- a blood test and urine sample collection.
- Where
- France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Liver Diseases, Liver Cirrhosis
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial.
- Conditions
- Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
- Trial name
- CHANCE (NCT04613921)
- Testing
- Observational Protocol
- Where
- 106 sites in United States, Argentina and 25 more
- Volunteers
- 3,000 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the…
- Trial name
- NCT06694974
- Testing
- APP calculation for FIB-4, Standard Care (in control arm)
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Primary Biliary Cholangitis (PBC)
Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)
The goal of this observational study is to achieve early diagnosis of Primary Biliary Cholangitis (PBC) in patients with positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP) in adults aged 18-80…
- Trial name
- NCT07205874
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Universitario La Paz
Cirrhosis, Liver, Cirrhotic Cardiomyopathy
Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis
Point-of-care echocardiography is used to guide septic shock resuscitation in patients with severe sepsis in the intensive care unit (ICU), but without systematic evidence for efficacy in critically patients with Cirrhosis and…
- Conditions
- Cirrhosis, Liver, Cirrhotic Cardiomyopathy, Septic Shock
- Trial name
- ECLIPSE-I (NCT07286643)
- Testing
- POCUS, Fixed Resuscitation Strategy based on Target MAP
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis
DOAC in Patients with Child a or B Liver Cirrhosis
The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with Child A or B liver cirrhosis (LC).
- Trial name
- CIRROAC (NCT05869591)
- Testing
- Apixaban 5 MG [Eliquis], Edoxaban 60 MG [Lixiana]
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Spontaneous Bacterial Peritonitis, Paracentesis
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous bacterial peritonitis (SBP) is a serious infection that occurs in patients with liver cirrhosis and ascites and is associated with substantial morbidity and mortality.
- Conditions
- Spontaneous Bacterial Peritonitis, Paracentesis, Treatment Efficacy, Adverse Events
- Trial name
- NCT07923318
- Testing
- Routine Follow-up Paracentesis at 48 Hours, Other
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Chonnam National University Hospital
Cirrhosis, Alcoholic Liver Disease
Intra-Hepatic Microbiota in Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a serious complication of alcoholic liver disease (ALD). The histological presentation of AH is characterized by neutrophilic lobular inflammation, macrovesicular steatosis, hepatocyte ballooning and…
- Conditions
- Cirrhosis, Alcoholic Liver Disease, Alcoholic Hepatitis
- Trial name
- HepMAH (NCT06307964)
- Testing
- Biological sampling
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Cirrhosis, HCC - Hepatocellular Carcinoma
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Conditions
- Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- NCT07132515
- Testing
- Enoxaparin, warfarrin, or apixaban
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Primary Biliary Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
The goal of this clinical study is to learn more about the study drug, seladelpar, and its effects on clinical outcomes in participants with primary biliary cholangitis (PBC) and compensated cirrhosis.
- Trial name
- AFFIRM (NCT06051617)
- Testing
- Seladelpar
- Where
- 218 sites in United States, Argentina and 27 more
- Volunteers
- 402 people
- Sponsor
- Gilead Sciences
Metabolic Dysfunction-Associated Liver Disease
Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes
Type 2 diabetes (T2DM) patients are at high-risk for advanced fibrosis (AF) due to non-alcoholic fatty liver disease (NAFLD), recently renamed Metabolic dysfunction-Associated Liver Disease (MASLD).
- Trial name
- DIATONIC (NCT06567990)
- Testing
- Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.
- Where
- 4 sites in France
- Volunteers
- 500 people
- Sponsor
- Hospices Civils de Lyon
Liver Cirrhosis, Refractory Ascites
Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot Study
Transjugular intrahepatic portosystemic shunt (TIPS) creation is an established minimally invasive treatment for complications of portal hypertension such as refractory ascites and variceal bleeding.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Variceal Bleeding, Portal Hypertension
- Trial name
- FLIGHT (NCT07470515)
- Testing
- Fiber-Optic Navigation System
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University Innsbruck
Liver Cirrhosis
SASL Swiss Cirrhosis Cohort
This is a national prospective long-term multicentre observational cohort study following patients with cirrhosis in order to systematically and longitudinally record epidemiological, clinical, histological, psychosocial and…
- Trial name
- SSCiCoS (NCT06092385)
- Testing
- Data collection
- Where
- 10 sites in Switzerland
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Primary Biliary Cholangitis (PBC)
Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)
The purpose of this study is to explore the use of digital health technology for measuring symptoms and daily health in people with primary biliary cholangitis (PBC).
- Trial name
- NCT07631442
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Non-hepatobiliary Indications
EUS-Guided ATI and SWE in Individuals With Normal FibroScan
The goal of this observational study is to establish preliminary reference values for Endoscopic Ultrasound (EUS)-guided Attenuation Imaging (ATI) and Shear Wave Elastography (SWE) in adults undergoing diagnostic EUS for…
- Trial name
- EUS ATI&SWE (NCT07714941)
- Testing
- Endoscopic Ultrasound (EUS), EUS-guided Attenuation Imaging (ATI), EUS-Guided Shear Wave Elastography (SWE)
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Asian Institute of Gastroenterology, India